Aug 2026· Molecular Imaging and Radionuclide Therapy· Vol 35, pp. 175 - 182· 0 citations· 16 references
Medicine
TL;DR
68Ga-FAPi PET/CT provides a significant advantage for staging and restaging breast cancer—especially lobular carcinoma and other low 18F-FDG-avid subtypes—supporting its potential role in clinical decision-making and treatment planning.
Abstract
Objectives Breast cancer is highly heterogeneous, and certain histopathologic subtypes—particularly invasive lobular carcinoma—exhibit low glucose metabolism that limits 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) performance. Fibroblast activation protein inhibitor (FAPi) imaging with Gallium-68 (68Ga)-FAPi PET/CT has emerged as a promising alternative for such tumors. The aim of this study was to evaluate the efficacy of 68Ga-FAPi PET/CT in staging, restaging, and recurrence detection of breast cancer, with emphasis on subtypes for which 18F-FDG PET/CT has low sensitivity. Methods Twenty-nine women with pathologically confirmed breast cancer (mean age 57.7±11.6 years) were prospectively enrolled. Histopathology (available in 24 patients) showed lobular carcinoma in 16, ductal carcinoma in 6, signet ring cell carcinoma in 1, and mucinous carcinoma in 1. All underwent both 68Ga-FAPi and 18F-FDG PET/CT within one week for staging or restaging. Maximum standardized uptake values (SUVmax) of primary tumors and metastases were recorded for both tracers and compared using paired t-tests. Results In 7/29 patients (24.1%), neither 18F-FDG PET/CT nor 68Ga-FAPi PET/CT detected pathological findings. Disease stage increased in 13/29 (44.8%) after 68Ga-FAPi PET/CT, including 10 patients with no pathologic findings on 18F-FDG PET/CT; nine were upstaged to stage 4 and one to stage 3. Additionally, one patient progressed from stage 1 to 2, one from 2 to 3, and another from 3 to 4. Among patients with lobular carcinoma, 8/16 (50%) were upstaged with 68Ga-FAPi PET/CT. Detection of nodal and distant metastases in lobular carcinoma was higher with 68Ga-FAPi than 18F-FDG. 68Ga-FAPi PET/CT also demonstrated higher SUVmax in primary lesions and metastases (p<0.05). Conclusion 68Ga-FAPi PET/CT provides a significant advantage for staging and restaging breast cancer—especially lobular carcinoma and other low 18F-FDG-avid subtypes—supporting its potential role in clinical decision-making and treatment planning.
In this small cohort, gallium-68 fibroblast activation protein inhibitor PET/CT showed a higher observed specificity than contrast-enhanced CT for the detection of locoregional LN metastases in gynecologic SCC, with no false-negative cases observed.
K. Michalski, A. Kosmala, P. Kohnle et al.· Anticancer Research· 0 citations
Early dynamic 18F-FDG PET/CT imaging at 0–2 min showed the highest, although modest, diagnostic performance among the evaluated time points for predicting tumor grade and muscle invasion.
B. Saylam, Berfin Temelli, Ali Nebi̇oğlu et al.· Medicina· 0 citations
This study aimed to evaluate the clinical value of fluorine-18-labeled fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) in managing primary malignant melanoma of the esophagus (PMME). Seventy patients with pathologically confirmed PMME between September 2011 and June 2025 were retrospectively analyzed. The dia...
Fei Wang, Xiang-Xi Meng, R. Guo et al.· Melanoma research· 0 citations
PET/CT using 68Ga-FAPI is a promising imaging modality for colorectal cancer, allowing detection of metastatic and additional suspicious lesions and assessment of dynamic changes during antitumor treatment.
Madina Altinbekova, T. Dautov, Z. Kozhakhmetova· Oncology, Nuclear Medicine a...· 0 citations
Neuroendocrine prostate cancer (NEPC) is a rare, aggressive subtype with hormonal resistance and poor prognosis. Traditional serum biomarkers such as prostate-specific antigen (PSA) and neuron-specific enolase (NSE) are often present at low or normal levels, making it difficult to accurately reflect disease burden an...
Yu-Qi Deng, Xin Li, Jie Hu et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.